Article Text

Download PDFPDF

P067/132  Cerebral vasospasm treatment using comaneci device – registry study
  1. Johannes Hensler1,
  2. Naomi Larsen1,
  3. Riedel Christian2,
  4. Hannes Nordmeyer3,
  5. Tobias Breyer4,
  6. Volker Hesselmann5,
  7. Höltje Jan6,
  8. Olav Jansen1
  1. 1University Hospital Schleswig-Holstein, Radiology and Neuroradiology, Kiel, Germany
  2. 2University Medical Center Göttingen, Department of Neuroradiology, Göttingen, Germany
  3. 3Radprax, St Lukas Klinik, Department of Interventional Neuroradiology , Solingen, Germany
  4. 4Klinikum Dortmund, Department of Radiology and Neuroradiology, Dortmund, Germany
  5. 5Asklepios Klinik Nord-Heidberg, Radiology and Neuroradiology, Hamburg, Germany
  6. 6University Hospital Schleswig-Holstein, Department of Neuroradiology, Lübeck, Germany


Introduction Subarachnoid haemorrhage (SAH) can result in cerebral vasospasms and delayed cerebral ischemia, which contribute significantly to morbidity and mortality. The effectiveness of endovascular treatment for this condition is still a subject of debate. However, the adjustable neck-bridging device Comaneci (Rapid Medical, Yokneam, Israel) may offer a safe and effective alternative to balloon angioplasty.

Aim of Study The Comaneci Registry Trial is the first multicentre registry designed to evaluate the clinical and radiologic safety and efficacy of Comaneci in angioplasty of cerebral vasospasm in a standardized manner in patients with severe cerebral vasospasm after SAH.

Methods All patients with severe vasospasm (>50%) in digital subtraction angiography (DSA) after aneurysmatic SAH treated with the Comaneci device as first-line therapy are included and evaluated through an angiographic vessel-by-vessel analysis using a 4-level scale as primary endpoint. All vessel-segments in anterior and posterior circulation up to M3-,A3- and P2-level are eligible for angioplasty with Comaneci. Clinical outcome is assessed with National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale mRS.

Results Although the study is still ongoing, the preliminary findings have demonstrated the safety and effectiveness of the treatment for vasospasm with Comaneci as a first-line angioplasty device.

Conclusion The Comaneci device has the potential to serve as a first-line device for providing therapeutic benefit to patients with SAH and vasospasm. However, future prospective trials are required.

Disclosure of Interest Nothing to disclose

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.